Cannabinoid Encyclopedia

How cannabinoids work

What is CB2?

A simple explanation of CB2, why cannabinoid researchers study it, and what its biology can and cannot tell us.

Updated July 2026 63 research sources Mostly early-stage research

The short answer

Where CB2 fits into cannabinoid biology

CB2 is a biological target studied to understand how cannabinoids affect cells and signaling. Research on THC, Anandamide, 2-AG, and Cannabinoids helps explain possible mechanisms. This page brings together 13 human-study sources, 25 research reviews, and 25 lab, animal, or mechanism sources. Most of the current evidence is preclinical or focused on biological mechanisms. A mechanism alone does not prove that a cannabinoid will produce a health benefit in people. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about CB2.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Research on CB2 covers THC, Anandamide, and 2-AG; those areas should not be combined into one claim. 1

  2. 2

    Most of the current evidence is preclinical or focused on biological mechanisms. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What researchers studied about CB2

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Mostly mechanism-focused

THC

Studies examine how THC connects with CB2 or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 2

Too limited for a firm answer

Anandamide

Studies examine how Anandamide connects with CB2 or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 3

Mostly mechanism-focused

2-AG

Studies examine how 2-AG connects with CB2 or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 4

Mostly mechanism-focused

Cannabinoids

Studies examine how Cannabinoids connects with CB2 or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 1

Mostly mechanism-focused

Endocannabinoids

Studies examine how Endocannabinoids connects with CB2 or closely related target biology. These findings help explain signaling and pharmacology, not a guaranteed health effect. 5

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

13 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

25 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

25 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

What these studies actually looked at

The research on CB2 is not one kind of study. This source set includes 25 narrative or expert reviews, 23 animal studies, and 5 cell or laboratory studies. 3

The recorded populations or models include animal models (19 sources), people or patients (17 sources), and cells or tissue models (9 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is cB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms (32 sources) and cB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms (31 sources). Closely related outcome names can still describe different measurements. 5

The CB2 source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

narrative or expert review

Cannabinoid receptor 2 (CB2) modulators: A patent review (2016-2024).

On this page, this source examines Cannabinoids activity involving CB2. 1

Study type
narrative or expert review
Outcome focus
cB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms
Evidence stage
evidence still limited

narrative or expert review

The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.

On this page, this source examines THC activity involving CB2. 2

Study type
narrative or expert review
Population or model
cells or tissue models
Outcome focus
cB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms
Evidence stage
evidence still limited

narrative or expert review

Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.

On this page, this source examines Anandamide activity involving CB2. 3

Study type
narrative or expert review
Population or model
animal models
Outcome focus
cB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms
Evidence stage
evidence still limited

animal study

Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli.

On this page, this source examines 2-AG activity involving CB2. 4

Study type
animal study
Population or model
animal models
Outcome focus
cB2 immune, inflammatory, microglial, neuroinflammatory, pain, or tissue-injury mechanisms
Evidence stage
mechanism-focused research

narrative or expert review

Cannabinergic ligands.

On this page, this source examines Endocannabinoids activity involving CB2. 5

Study type
narrative or expert review
Population or model
cells or tissue models
Outcome focus
cB2 receptor pharmacology, ligand binding, selectivity, or signaling mechanisms
Evidence stage
evidence still limited

Safety and limits

What should readers keep in mind?

Research on CB2 should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What does CB2 do?

CB2 is studied as part of cannabinoid-related biology and signaling. The exact role depends on the tissue, compound, and experimental setting. 7

Does a biological mechanism prove a health effect?

No. A mechanism can explain why an idea is plausible, but human studies are needed to test whether it changes a health outcome. 8

What research is linked to CB2?

The main areas on this page include THC, Anandamide, 2-AG, and Cannabinoids. The source links show the study type behind each area. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Cannabinoid receptor 2 (CB2) modulators: A patent review (2016-2024). narrative or expert review; evidence still limited PubMed 39288632 DOI 10.1016/j.bioorg.2024.107775
  2. 2
    The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. narrative or expert review; evidence still limited PubMed 17828291 DOI 10.1038/sj.bjp.0707442
  3. 3
    Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. narrative or expert review; evidence still limited PubMed 16678907 DOI 10.1016/j.plipres.2006.03.003
  4. 4
    Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. animal study; mechanism-focused research PubMed 16086683 DOI 10.1111/j.1471-4159.2005.03380.x
  5. 5
    Cannabinergic ligands. narrative or expert review; evidence still limited PubMed 12505686 DOI 10.1016/s0009-3084(02
  6. 6
    An Introduction to the Endogenous Cannabinoid System. narrative or expert review; evidence still limited PubMed 26698193 DOI 10.1016/j.biopsych.2015.07.028
  7. 7
    An overview of the cannabinoid type 2 receptor system and its therapeutic potential. narrative or expert review; evidence still limited PubMed 29794855 DOI 10.1097/aco.0000000000000616
  8. 8
    Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. narrative or expert review; evidence still limited PubMed 18537620 DOI 10.2174/092986708784567716
  9. 9
    Cannabinoid CB2 receptor orthologues; in vitro function and perspectives for preclinical to clinical translation. narrative or expert review; evidence still limited PubMed 37349984 DOI 10.1111/bph.16172
  10. 10
    Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update. narrative or expert review; evidence still limited PubMed 27215781 DOI 10.1080/13543776.2016.1193157
  11. 11
    Cannabinoid Receptor 2 (CB2) in Macrophages: A Promising Clinical Target for Immune Disorders. narrative or expert review; evidence still limited PubMed 40943579 DOI 10.3390/ijms26178657
  12. 12
    Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection? narrative or expert review; evidence still limited PubMed 32471272 DOI 10.3390/ijms21113809
See all 63 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. narrative or expert review; evidence still limited / 1 linked research note PubMed 17828291
  2. Cannabinoid receptor 2 (CB2) modulators: A patent review (2016-2024). narrative or expert review; evidence still limited / 1 linked research note PubMed 39288632
  3. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists. narrative or expert review; evidence still limited / 1 linked research note PubMed 18537620
  4. An Introduction to the Endogenous Cannabinoid System. narrative or expert review; evidence still limited / 1 linked research note PubMed 26698193
  5. Cannabichromene is a cannabinoid CB2 receptor agonist. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 31368508
  6. Cannabinergic ligands. narrative or expert review; evidence still limited / 1 linked research note PubMed 12505686
  7. Pharmacology of cannabinoid receptor ligands. narrative or expert review; evidence still limited / 1 linked research note PubMed 10469884
  8. Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists. narrative or expert review; evidence still limited / 1 linked research note PubMed 33811300
  9. A universal cannabinoid CB1 and CB2 receptor TR-FRET kinetic ligand-binding assay. mechanism-focused research / 1 linked research note PubMed 40271066
  10. Functional Selectivity at Cannabinoid Receptors. narrative or expert review; evidence still limited / 1 linked research note PubMed 28826535
  11. Pharmacology of cannabinoid CB1 and CB2 receptors. narrative or expert review; evidence still limited / 1 linked research note PubMed 9336020
  12. CB2 cannabinoid receptor agonist enantiomers HU-433 and HU-308: An inverse relationship between binding affinity and biological potency. animal study; mechanism-focused research / 1 linked research note PubMed 26124120
  13. The Spicy Story of Cannabimimetic Indoles. narrative or expert review; evidence still limited / 1 linked research note PubMed 34684770
  14. Crystal Structure of the Human Cannabinoid Receptor CB2. mechanism-focused research / 1 linked research note PubMed 30639103
  15. Cryo-EM Structure of the Human Cannabinoid Receptor CB2-Gi Signaling Complex. mechanism-focused research / 1 linked research note PubMed 32004460
  16. Human Cannabinoid Receptor 2 Ligand-Interaction Motif: Transmembrane Helix 2 Cysteine, C2.59(89), as Determinant of Classical Cannabinoid Agonist Activity and Binding Pose. mechanism-focused research / 1 linked research note PubMed 28220706
  17. A Cannabinoid Type 2 (CB2) Receptor Agonist Augments NOS-Dependent Responses of Cerebral Arterioles During Type 1 Diabetes. animal study; mechanism-focused research / 1 linked research note PubMed 36889269
  18. CB2 cannabinoid receptor agonist selectively inhibits the mechanosensitivity of mucosal afferents in the guinea pig bladder. mechanism-focused research / 1 linked research note PubMed 33749323
  19. CB2 cannabinoid receptor-mediated peripheral antinociception. mechanism-focused research / 1 linked research note PubMed 11514083
  20. Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update. narrative or expert review; evidence still limited / 1 linked research note PubMed 27215781
  21. CB2 cannabinoid receptor mediation of antinociception. animal study; mechanism-focused research / 1 linked research note PubMed 16563625
  22. The Cannabinoid-2 receptor agonist, 1-phenylisatin, protects against cisplatin-induced nephrotoxicity in mice. animal study; mechanism-focused research / 1 linked research note PubMed 36058263
  23. Cannabinoid Receptor Type 2 Agonist Reduces Morphine Tolerance via Mitogen Activated Protein Kinase Phosphatase Induction and Mitogen Activated Protein Kinase Dephosphorylation. mechanism-focused research / 1 linked research note PubMed 34774714
  24. The cannabinoid CB2 receptor-specific agonist AM1241 increases pentylenetetrazole-induced seizure severity in Wistar rats. animal study; mechanism-focused research / 1 linked research note PubMed 27608434
  25. The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. mechanism-focused research / 1 linked research note PubMed 20849866
  26. Structural basis of selective cannabinoid CB2 receptor activation. mechanism-focused research / 1 linked research note PubMed 36922494
  27. Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016-present). narrative or expert review; evidence still limited / 1 linked research note PubMed 38886185
  28. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. narrative or expert review; evidence still limited / 1 linked research note PubMed 16678907
  29. Cannabinoid CB2 receptor orthologues; in vitro function and perspectives for preclinical to clinical translation. narrative or expert review; evidence still limited / 1 linked research note PubMed 37349984
  30. Recent Advances on Type-2 Cannabinoid (CB2) Receptor Agonists and their Therapeutic Potential. narrative or expert review; evidence still limited / 1 linked research note PubMed 36028971
  31. The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonists as New Psychoactive Substances: Origins. narrative or expert review; evidence still limited / 1 linked research note PubMed 29980914
  32. Structural requirements for cannabinoid receptor probes. narrative or expert review; evidence still limited / 1 linked research note PubMed 16596776
  33. Modulation of cannabinoid receptor 2 alters neuroinflammation and reduces formation of alpha-synuclein aggregates in a rat model of nigral synucleinopathy. animal study; mechanism-focused research / 1 linked research note PubMed 39334169
  34. Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. narrative or expert review; evidence still limited / 1 linked research note PubMed 19152719
  35. Type 2 cannabinoid receptor expression on microglial cells regulates neuroinflammation during graft-versus-host disease. animal study; mechanism-focused research / 1 linked research note PubMed 38662453
  36. CB₂: therapeutic target-in-waiting. narrative or expert review; evidence still limited / 1 linked research note PubMed 22197668
  37. Cannabinoid CB2 receptors enhance high-fat diet evoked peripheral neuroinflammation. animal study; mechanism-focused research / 1 linked research note PubMed 39173999
  38. Emerging roles of cannabinoid receptor CB2 receptor in the central nervous system: therapeutic target for CNS disorders. narrative or expert review; evidence still limited / 1 linked research note PubMed 39264450
  39. Cannabinoid receptor 2 evolutionary gene loss makes parrots more susceptible to neuroinflammation. mechanism-focused research / 1 linked research note PubMed 36475439
  40. Cannabinoid CB2 receptors modulate alcohol induced behavior, and neuro-immune dysregulation in mice. animal study; mechanism-focused research / 1 linked research note PubMed 37061199
  41. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. animal study; mechanism-focused research / 1 linked research note PubMed 18615177
  42. Cannabinoid receptor 2 activation mitigates lipopolysaccharide-induced neuroinflammation and sickness behavior in mice. animal study; mechanism-focused research / 1 linked research note PubMed 30666359
  43. An overview of the cannabinoid type 2 receptor system and its therapeutic potential. narrative or expert review; evidence still limited / 1 linked research note PubMed 29794855
  44. Conditional deletion of CB2 cannabinoid receptors from peripheral sensory neurons eliminates CB2-mediated antinociceptive efficacy in a mouse model of carrageenan-induced inflammatory pain. animal study; mechanism-focused research / 1 linked research note PubMed 37286073
  45. Up-regulation of immunomodulatory effects of mouse bone-marrow derived mesenchymal stem cells by tetrahydrocannabinol pre-treatment involving cannabinoid receptor CB2. animal study; mechanism-focused research / 1 linked research note PubMed 26824325
  46. CB1 and CB2 cannabinoid receptor antagonists prevent minocycline-induced neuroprotection following traumatic brain injury in mice. animal study; mechanism-focused research / 1 linked research note PubMed 23960212
  47. Enantiomeric Agonists of the Type 2 Cannabinoid Receptor Reduce Retinal Damage during Proliferative Vitreoretinopathy and Inhibit Hyperactive Microglia In Vitro. animal study; mechanism-focused research / 1 linked research note PubMed 38751621
  48. The development of cannabinoid CBII receptor agonists for the treatment of central neuropathies. narrative or expert review; evidence still limited / 1 linked research note PubMed 20236042
  49. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. animal study; mechanism-focused research / 1 linked research note PubMed 12823482
  50. Cannabinoid Type 2 Receptor System Modulates Paclitaxel-Induced Microglial Dysregulation and Central Sensitization in Rats. animal study; mechanism-focused research / 1 linked research note PubMed 30414958
  51. Cannabidiol-rich non-psychotropic Cannabis sativa L. oils attenuate peripheral neuropathy symptoms by regulation of CB2-mediated microglial neuroinflammation. animal study; mechanism-focused research / 1 linked research note PubMed 36583304
  52. A sesquiterpene-rich essential oil from Cannabis sativa L. attenuates symptoms and neuroinflammation in experimental autoimmune encephalomyelitis model through a CB2-mediated signalling. animal study; mechanism-focused research / 1 linked research note PubMed 41875735
  53. Effects of CB2 Receptor Modulation on Macrophage Polarization in Pediatric Inflammatory Bowel Disease. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 40332343
  54. CB2 cannabinoid receptor-specific therapeutic antibody agonists for treatment of chemotherapy-induced peripheral neuropathy. animal study; mechanism-focused research / 1 linked research note PubMed 41383775
  55. What we know and do not know about the cannabinoid receptor 2 (CB2). narrative or expert review; evidence still limited / 1 linked research note PubMed 24877594
  56. Cannabinoid Receptor 2 Activating Antibodies: A Promising Therapeutic Strategy for Macrophage-Driven Fibro-Inflammatory Diseases. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 40791361
  57. Cannabinoid Receptor 2 (CB2) in Macrophages: A Promising Clinical Target for Immune Disorders. narrative or expert review; evidence still limited / 1 linked research note PubMed 40943579
  58. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. animal study; mechanism-focused research / 1 linked research note PubMed 16086683
  59. Cannabinoid receptor 2 affect the inflammatory response in periodontitis by regulating macrophage M1/M2 polarization. animal study; mechanism-focused research / 1 linked research note PubMed 41310604
  60. The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor. animal study; mechanism-focused research / 1 linked research note PubMed 18247131
  61. Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection? narrative or expert review; evidence still limited / 1 linked research note PubMed 32471272
  62. Cannabinoid receptor type 2 agonist GP1a attenuates macrophage activation induced by M. bovis-BCG by inhibiting NF-κB signaling. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 39538989
  63. Cannabinoid receptor 2 activating antibodies: A promising therapeutic strategy for macrophage-driven fibro-inflammatory diseases. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 41740200